Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma

Br J Cancer. 1992 Dec;66(6):1177-9. doi: 10.1038/bjc.1992.431.

Abstract

The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Renal Cell / blood*
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / therapy
  • Female
  • Humans
  • Injections, Subcutaneous
  • Interleukin-2 / administration & dosage*
  • Kidney Neoplasms / blood*
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / therapy
  • Leukocyte Count
  • Lymphocyte Subsets*
  • Male
  • Middle Aged
  • Phenotype
  • Recombinant Proteins / administration & dosage

Substances

  • Interleukin-2
  • Recombinant Proteins